Ozempic: A Potential Ally in Lowering Depression Risk, Reveals Major Study
Weight loss medication Ozempic may offer surprising mental health benefits beyond its weight management effects, according to groundbreaking research published in The Lancet Psychiatry on May 4, 2026.
The massive study, which tracked nearly 100,000 individuals over 13 years, found that people taking semaglutide—the active ingredient in Ozempic and Wegovy—experienced a 44% reduction in depression risk and a 42% decrease in psychiatric hospital visits compared to periods when they weren’t using the medication. Anxiety disorders were reduced by 38%, while substance use disorders requiring hospitalization or work absence dropped by an impressive 47%.
Conducted by researchers from the University of Eastern Finland, Karolinska Institutet in Sweden, and Griffith University in Australia, the study analyzed Swedish health records from 2009 to 2022. The research revealed that during periods of semaglutide use, psychiatric-related hospital care and sick leave dropped by 42% overall.
Scientists suggest multiple mechanisms could explain these mental health improvements, including:
- Weight loss-related improvements in body image
- Reduced alcohol consumption
- Better glycemic control in diabetes patients
- Possible direct neurobiological effects on the brain’s reward system
Professor Mark Taylor from Griffith University noted this provides ‘a strong suggestion that they could be considered as treatments for depression or anxiety in the diabetic or obese populations,’ though controlled clinical trials are still needed to confirm causality.
Source: ScienceDaily